LANGHORNE -
Savara's partner,
Below are summaries of the posters presented: Poster Board 701: 'Healthcare Burden of Pulmonary Alveolar Proteinosis' presented by
Presented data from a retrospective cohort analysis using a longitudinal claims database (IPM.ai) comparing the clinical and economic burden of a sample of 2,312 pulmonary alveolar proteinosis (PAP) patients to 9,247 non-PAP matched controls.
Data demonstrated PAP patients experience higher healthcare resource utilization and higher pharmaceutical and non-pharmaceutical costs as evidenced by a 4-fold increase in hospital admissions, 6-fold increase in in-patient visits, and a 4-fold increase in cost of care, as well as higher rates of comorbidities, procedures, and therapy use (all parameters p
(C) 2024 Electronic News Publishing, source